Safety and Efficacy of Degradable Microsphere in Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma

Hepatocellular Carcinoma Clinical Trial

Official title:

Safety and Efficacy of Degradable Microsphere in Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma: a Prospective Comparative Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05072041
• Other study ID #: NEXTBIO-UIGB-HCC01
• Status: Recruiting
• Phase: N/A
• Start date: October 31, 2021
• Est. completion date: December 31, 2025

Study information

• Verified date: July 2023
• Source: Next Biomedical Co., Ltd.
• Contact: Jin Hee Maeng, MS
• Phone: +8228800860
• Email: jhmaeng[@]nextbiomedical.co.kr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study was to prospectively collect clinical data from patients who underwent hepatic artery chemoembolization using microspheres with different degradation times (2 hours, 1 day, 2 weeks) based on standard treatment.

Description:

This study is a prospective study, and the purpose of this study is to investigate and collect clinical information on the safety and efficacy of degradable microsphere for hepatic artery chemoembolization in hepatocellular carcinoma patients. The primary purpose of this study was to evaluate the incidence of postembolism syndrome and liver function impairment after hepatic artery chemoembolization, and the secondary purpose was to evaluate tumor treatment response and hepatic artery damage after 1 month of hepatic artery chemoembolization.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 150
• Est. completion date: December 31, 2025
• Est. primary completion date: August 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 19 Years to 79 Years

Eligibility

Inclusion Criteria:

1. Adult patients aged 19 to 79 years

2. Patient who signed Informed Consent Form

3. Patients diagnosed with hepatocellular carcinoma by American Association for the Study of Liver Diseases (AASLD) and at least one of the following methods i. Magnetic resonance imaging (MRI) with early augmentation and delayed excretion of at least one solid liver lesion greater than 1 ?. ii. Contrast-enhanced computed tomography (CT) with early augmentation and delayed build-up of at least one solid liver lesion >1 ?. iii. Lesions with inconclusive features require histological confirmation.

4. Patients should not be eligible for treatment by amputation or percutaneous resection or liver transplantation at the time of study enrollment. i. Patients who are not suitable for ablation due to lesion location may be enrolled. ii. Patients with recurrent hepatocellular carcinoma who are not suitable for amputation or resection may be enrolled.

5. Must be Child-Pugh A or B hepatocellular carcinoma, and must satisfy the following criteria. i. Tumor lesion size from 1 ? to 10 ? ii. Number of tumors 1-7 iii. Physical activity European Cooperative Oncology Group (ECOG) = 1 without vascular involvement

6. Patients who can be followed up until the end of the study and whose life expectancy is 6 months or longer

Exclusion Criteria:

1. Patients under the age of 19

2. Chronic kidney disease (CDK) grade 4 or 5 patients

3. Current or previous treatment with chemotherapy or radiation therapy or sorafenib or drug release chemoembolization (deTACE) after diagnosis of hepatocellular carcinoma

5. Pregnant, lactating, pre-menopausal and women not using effective contraceptive methods

6. Performance state European Cooperative Oncology Group (ECOG) > 1 7. Child-Poo Class C 8. Advanced hepatocellular carcinoma with vascular invasion or extrahepatic metastasis 9. Active Gastrointestinal Bleeding 10. Evidence of irreversible bleeding constitution 11. Encephalopathy that is not medically adequately controlled 12. Presence of ascites that is not medically controlled 13. Contraindications to Magnetic Resonance Imaging or Computed Tomography scan (e.g. metal implants) 14. Allergy to contrast media that cannot be managed by prevention 15. Contraindications to angiography 16. Contraindications to the administration of cisplatin anticancer drugs 17. Contraindications to hepatic artery embolization

• Extensive context-to-systemic shunts
• hepatofugal portal blood flow
• Serum bilirubin > 3.0 ?/dL
• Serum creatinine > 2.0 ?/dL
• Other symptoms that your doctor has determined to be exclusive.
• Irreversible blood clotting disorders 18. Others who are judged to be difficult for the principal investigator or principal investigator to conduct this clinical trial for other reasons

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular
• Hepatocellular Carcinoma

Intervention

Device:
• Nexsphere™
Nexsphere™ is a yellow powder, made of 100% hydrophilic gelatin. It is used to make a suspension by mixing a contrast agent and physiological saline. The indications are hepatic artery chemoembolization, uterine artery embolization, prostate artery embolization, and treatment of various hemorrhagic diseases. It physically embolizes blood vessels and is decomposed within 4-8 weeks after intravascular injection.

Locations

Country	Name	City	State
Korea, Republic of	Asan Medical Center	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Next Biomedical Co., Ltd.

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of postembolism syndrome	Nausea, vomiting, persistent pain, fever, and other	8 weeks
Primary	Incidence of liver function impairment	AFP, AST, ALT, BILI, GGT, BUN, and CREAT level	8 weeks
Secondary	Tumor treatment response	Evaluation of tumor size by Magnetic Resonance Imaging or Computed Tomography scan at 4 and 8 weeks after embolization	8 weeks
Secondary	Hepatic artery damage	Vessel dissection, vessel stenosis, vessel occlusion, vessel wall irregularity, and other	8 weeks